Author: KEI Staff
2015: Kassy Perry, speaking on behalf of ?, opposing AB 463, on transparency of drug R&D costs and subsidies
During the debate of California bill AB 463, on the Pharmaceutical Cost Transparency Act of 2015, Kassy Perry was using Twitter to attack the bill, posting links to and repeating pharmaceutical industry talking points. Who is Kassy Perry? A founder of Perry Communications, a Sacramento public relations and lobbying firm. This is her Twitter profile:
Sony referred to “WIPO treaty for blind as “stalking horse” to “denigrate the rights of copyright owners”
In the new Wikileaks archives of leaked Sony documents (Link here), there is a memo (https://wikileaks.org/sony/docs/05/docs/DECE/DECE%20CP1%20-%20ss.doc.pdf), which describes Sony Pictures Entertainment (SPE) concern over the proposed WIPO treaty for copyright exceptions for persons who are blind or have other disabilities. The memo, undated in the Wikileaks archives, but probably written in 2009, included the following passages:
2014 Oct 3 version: Regional Comprehensive Economic Partnership, Japan IPR proposals, RCEP
(More KEI RCEP leaks here: /rcep)
Attached is a leaked version of Japan’s October 3, 2014 proposals for intellectual property for the Regional Comprehensive Economic Partnership.
Patents with government interests, by disease, 2010 to 2013
The attached PDF file provides counts on the number of patents with various search terms in the specification (spec/”search term”), and the number of those patents that declare either government rights in the patents (govt/government), an assignment to the US government (an/”united states of america”), or both. The complete counts are in the PDF file. The queries were done by Claire Cassedy on December 5, 2014.
KEI Research Note: Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results
A copy of the research note is also available here as a pdf file: /wp-content/uploads/kei-rn-2014-3.pdf
KEI Research Note 2014:3
Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results
Elizabeth Rajasingh
November 17, 2014
Introduction
Rajasingh on India-US dispute over patents on dasatinib, a drug to treat leukemia
link to video: https://www.youtube.com/watch?v=vU-JLDq02CE See also: /node/2109.
Video script:
My name is Elizabeth Rajasingh.
I want to talk about a trade dispute between India and the United States, involving patents on a drug for leukemia.
Comments to USTR on the Out-of-Cycle Review for India due October 31, 2014.
|
| Ambassador Michael Froman wants to block compulsory licenses on drug patents in India |